Preclinical in vitro and in vivo screening assays for cancer preventive agent development
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261200433002C
- Awardee
-
Weill Medical College Of Cornell University UEI YNT8TCJH8FQ8 Part of Cornell University
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,705,815
Award facts
- Opportunity
-
- N01CN2502676 Solicitation number
- Contract value 32% obligated
-
- $33,547,932.27 Current, with exercised options
- $36,289,060.27 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers
- Pricing
- Cost No Fee
- Place of performance
- New York, NY 10065, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $2,702,092 | |
| Supplemental Agreement for work within scope | $2,562,872 | |
| Funding Only Action | $1,415,128 | |
| Funding Only Action | $76,942 | |
| Funding Only Action | $1,249,058 | |
| Funding Only Action | $1,237,000 | |
| Funding Only Action | $1,249,559 | |
| Other Administrative Action | -$4,272 | |
| Original award | $1,213,164 |
Show all 13
About this award
This is a definitive cost-no-fee contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute to Weill Medical College of Cornell University, a private research university, for preclinical in vitro and in vivo screening assays to support the development of cancer preventive agents. The contract has a potential value of $36,289,060.27 and a completion date of October 31, 2012. It is not set aside for any specific business type.
The contract is part of the National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program, which aims to advance cancer preventive drugs and vaccines from discovery to clinical trials using a structured approach. Under this contract, Weill Medical College provides a range of preclinical research services, including efficacy testing, biomarker evaluation, and analytical assay development, across three separate contract pools: the PREVENT Efficacy Pool, PREVENT CGMP Pool, and PREVENT Toxicology and Pharmacology Pool. These research activities help transition promising cancer preventive agents through the preclinical stage.
Quick answers
Who was awarded contract HHSN261200433002C?
HHSN261200433002C was awarded to Weill Medical College Of Cornell University by National Cancer Institute (National Institutes of Health) on April 30, 2004.
How much is contract HHSN261200433002C worth?
The government has obligated $11,705,815 on HHSN261200433002C. Its current value, with exercised options, is $33,547,932. Its potential value, with all options, is $36,289,060.
Was contract HHSN261200433002C competed?
The extent of competition for HHSN261200433002C was full and open competition. The government received 6 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award